UNSPSC 51281502: Isoniazid

This classification denotes an antitubercular agent with the molecular formula C6H7N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V83O1VOZ8L, chemically known as 4-pyridinecarboxylic acid, hydrazide but generally known as isoniazid, which bears US NIH Compound Identifier 3767. European Medicines Agency schedules Isoniazid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08326MIG. The term ISONIAZID is an International Non-Proprietary Name.

UNSPSC 51281502 Isoniazid, a Commodity code, nominally addresses a specific anti-tuberculosis medication but shows no recent state and local procurement activity directly aligned with that narrow product scope. The recent opportunities tagged to this code involve substantially different pharmaceutical and medical supply categories: emergency response supplies for first responders, naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription programs. The issuing bodies span state health and human services commissions, county health departments, municipal fire departments, and cooperative purchasing alliances operating across multiple states. The actual procurement activity under this code frame reflects broad-based state and local demand for medical supplies, emergency pharmaceuticals, and pharmacy program infrastructure rather than isoniazid specifically.

The geographic spread includes Florida (Seminole County), Texas (HHS Commission), Minnesota and Oregon (MMCAP cooperative), and distributed across the Tampa Bay and central Florida regions. Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (1,900 units of naloxone and 800 deactivation systems annually, response due July 26, 2026); the City of Tampa's IFB for medical and first aid supplies for the Fire Department Rescue Division (169 line items, $700 million estimated contract, sheltered to certified Small Local Business Enterprises with a 5 percent bid discount, due March 13, 2026); MMCAP's RFP for generic multi-source pharmaceuticals and OTC products across participating state and local facilities (responses due March 26, 2026, contract term two years with optional extensions through June 30, 2028); and Texas HHS Commission's RFI for direct-to-manufacturer prescription programs (response due April 3, 2026). The code shows active procurement momentum but with little direct relevance to isoniazid procurement itself, suggesting a tagging mismatch between the nominal commodity and the work actually being solicited.